hot off the press ScoPo’s Powerplay – 2023 market darling...

hot off the press

ScoPo’s Powerplay – 2023

market darling NeurenMarket darling of the ASX biotech sector for 2023 Neuren Pharmaceuticals (ASX:NEU) is Power’s pick of the week.In March, NEU announced that its North American partner Acadia Pharma received a historic US FDA approval of trofinetide, marketed as DAYBUE, making the drug the first and only approved treatment for Rett syndrome in the world.NEU has now completed enrolments for its Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome with topline results forecast for December.“We think it will get into the ASX 200 in the September re-balance so that will be positive for them,” he says.“We expect the readout for NNZ-2591 to be positive in December so news flow rich for the remainder of the year.”